Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long ‐Term Registry: bridging between EMA/FDA label, the PARADIGM‐HF trial, ESC Guidelines, and real‐world

ConclusionsAmong outpatients with HFrEF in the ESC ‐HFA‐HF‐LT registry, 84% met label criteria, while only 12% and 28% met PARADIGM‐HF and Guidelines criteria for LCZ696 if requiring ≥20 mg and ≥10 mg enalapril, respectively. Registry patients eligible for LCZ696 had greater HF hospitalization but lower mortality rates then the PARADIGM‐ HF enalapril group.

Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Authors: Chris J. Kapelios, Mitja Lainscak, Gianluigi Savarese, C écile Laroche, Petar Seferovic, Frank Ruschitzka, Andrew Coats, Stefan D. Anker, Maria G. Crespo‐Leiro, Gerasimos Filippatos, Massimo F. Piepoli, Giuseppe Rosano, Luisa Zanolla, Carl Tags: Research Article Source Type: research